PRESS RELEASE: US federal appeals court temporarily stops Teva from selling its generic version of fAMVIR

US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir

US Court of Appeals for the Federal Circuit issues order prohibiting Teva from selling its generic version

Novartis holds valid US patents until 2015 for Famvir®, an antiviral medicine

Basel, September 10, 2007 - A US federal appeals court has approved a request by Novartis and temporarily prohibited Teva Pharamceuticals from selling its generic version of the antiviral medicine Famvir®, which has various US patents valid until 2015.
 
The order issued on September 7 by the US Court of Appeals for the Federal Circuit, which has nationwide jurisdiction in various subject areas that include patents, requires Teva to submit a response to the court by Tuesday, September 11.
 
The injunction remains in effect until a decision by this court. Teva launched its generic version "at risk" since patent litigation is still ongoing, and risks potentially significant damages if Novartis prevails. A trial date has not been set.
 
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "will," "expected," or similar expressions, or by express or implied discussions regarding potential further revenues from Famvir or the potential impact of the US District Court decision and Teva's actions on Novartis AG's net sales, operating income, net income and business generally. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Famvir and the impact of Teva's actions and the US District Court decision to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Famvir will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Famvir and the impact of the US District Court decision and Teva's actions could be affected by, among other things, further decisions by the US District Court with respect to the patent infringement litigation, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
 
About Novartis
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ more than 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.